Our finding that higher myostatin levels are associated with poorer response to mepolizumab might imply that these patients met criteria for eosinophilic asthma based on their peripheral eosinophil counts but that the underlying mechanism driving their asthma is neutrophilic or mixed granulocytic [13, 32]. This evidence concerns the gene MSTN and asthma.